Regeneron Scores Injunctions in Eylea Biosimilar Patent Fight

Samsung Bioepis Co. was hit with a preliminary injunction in Regeneron Pharmaceuticals Inc.‘s patent-infringement lawsuit over proposed biosimilars to its Eylea age-related macular degeneration treatment, days after Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. received permanent injunctions.

Chief Judge Thomas S. Kleeh of the US District Court for the Northern District of West Virginia granted Regeneron’s requests for the injunctions, according to sealed docket entries Friday and June 11.

Regeneron sought to block its rivals’ sales of their copies, and last month narrowed its bid to a single patent, US Patent No. 11,084,865.

Kleeh on Friday granted a ...